Vβ14+ T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin-inactivated RSV

Journal of Virology

Volumn 78, Issue 16, 2004, Pages 8753-8760

  Johnson, Teresa R ^a   Varga, Steven M ^b,c   Braciale, Thomas J ^b   Graham, Barney S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EOTAXIN; FORMALDEHYDE; GAMMA INTERFERON; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PROTEIN VBETA14; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS GLYCOPROTEIN G; INACTIVATED VACCINE; LYMPHOCYTE ANTIGEN RECEPTOR; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DELETION MUTANT; DISEASE SEVERITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOPATHOLOGY; LOEFFLER PNEUMONIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; STATISTICAL SIGNIFICANCE; ANIMAL; BAGG ALBINO MOUSE; IMMUNOLOGY; METABOLISM; PATHOPHYSIOLOGY; T LYMPHOCYTE; VIRUS INFECTION;

ANIMALS; FORMALDEHYDE; IMMUNIZATION; MICE; MICE, INBRED BALB C; PULMONARY EOSINOPHILIA; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; T-LYMPHOCYTES; VACCINES, INACTIVATED; VIRAL PROTEINS;

EID: 3543120025     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.16.8753-8760.2004     Document Type: Article

References (55)

1. Alwan, W. H., W. J. Kozlowska, and P. J. M. Openshaw. 1994. Distinct types of lung disease caused by functional subsets of antiviral T cells. J. Exp. Med. 179:81-89.
2. Bangham, C. R. M., M. J. Cannon, D. T. Karzon, and B. A. Askonas. 1985. Cytotoxic T-cell response to respiratory syncytial virus in mice. J. Virol. 56:55-59.
3. Bangham, C. R. M., P. J. M. Openshaw, A. Ball, A. M. Q. King, G. W. Wertz, and B. A. Askonas. 1986. Human and murine cytotoxic T cells specific to respiratory syncytial virus recognize the viral nucleoprotien (N), but not the major glycoprotein (G), expressed by vaccinia virus recombinants. J. Immunol. 137:3973-3977.
4. Bembridge, G. P., R. Garcia-Beato, J. A. Lopez, J. A. Melero, and G. Taylor. 1998. Subcellular site of expression and route of vaccination influence pulmonary eosinophilia following respiratory syncytial virus challenge in BALB/c mice sensitized to the attachment G protein. J. Immunol. 161:2473-2480.
5. Cannon, M. J., P. J. M. Openshaw, and B. A. Askonas. 1988. Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus. J. Exp. Med. 168:1163-1168.
6. Carrion, F., M. Fernandez, M. Iruretagoyena, L. E. Coelho Andrade, M. Odete-Hilario, and F. Figueroa. 2003. Selective depletion of Vβ2+CD8+ T cells in peripheral blood from rheumatic heart disease patients. J. Autoimmun. 20:183-190.
7. Cherrie, A. H., K. Anderson, G. W. Wertz, and P. J. M. Openshaw. 1992. Human cytotoxic T cells stimulated by antigen on dendritic cells recognize the N, SH, F, M, 22K, and 1b proteins of respiratory syncytial virus. J. Virol. 66:2102-2110.
8. Connors, M., P. L. Collins, C.-Y. Firestone, A. V. Sotnikov, A. Waitze, A. R. Davis, P. P. Hung, R. M. Chanock, and B. R. Murphy. 1992. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia-RSV recombinants or RSV. Vaccine 10:475-484.
9. Connors, M., N. A. Giese, A. B. Kulkarni, C.-Y. Firestone, I. Morse, and B. R. Murphy. 1994. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J. Virol. 68:5321-5325.
10. + T lymphocytes. Immunology 108:220-229.
11. Gomez, F. J., J. A. Cain, R. S. Gibbons, R. Allendoerfer, and G. S. Deepe, Jr. 1998. Vbeta4(+) T cells promote clearance of infection in murine pulmonary histoplasmosis. J. Clin. Investig. 102:984-995.
12. + T cells exert cooperative activity in clearance of secondary infection with Histoplasma capsulatum. J. Immunol. 166:2855-2862.
13. Graham, B. S., G. S. Henderson, Y.-W. Tang, X. Lu, K. M. Neuzil, and D. G. Colley. 1993. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J. Immunol. 151:2032-2040.
14. Graham, B. S., M. D. Perkins, P. F. Wright, and D. T. Karzon. 1988. Primary respiratory syncytial virus infection in mice. J. Med. Virol. 26:153-162.
15. Graham, B. S., J. A. Rutigliano, and T. R. Johnson. 2002. Respiratory syncytial virus immunobiology and pathogenesis. Virology 297:1-7.
16. Hall, C. B. 2001. Respiratory syncytial virus and parainfluenza virus. N. Engl. J. Med. 344:1917-1928.
17. Hancock, G. E., D. J. Speelman, K. Heers, E. Bortell, J. Smith, and C. Cosco. 1996. Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus. J. Virol. 70:7783-7791.
18. Hendricks, D. A., K. Baradaran, K. McIntosh, and J. L. Patterson. 1987. Appearance of a soluble form of the G protein of respiratory syncytial virus in fluids of infected cells. J. Gen. Virol. 68:1705-1714.
19. Hussell, T., A. Georgiou, T. E. Sparer, S. Matthews, P. Pala, and P. J. M. Openshaw. 1998. Host genetic determinants of vaccine-induced eosinophilia during respiratory syncytial virus infection. J. Immunol. 161:6215-6222.
20. Johnson, P. R., R. A. Olmsted, G. A. Prince, B. R. Murphy, D. W. Alling, E. E. Walsh, and P. L. Collins. 1987. Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity. J. Virol. 61:3163-3166.
21. Johnson, P. R., M. K. Spriggs, R. A. Olmsted, and P. L. Collins. 1987. The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins. Proc. Natl. Acad. Sci. USA 84:5625-5629.
22. Johnson, T. R., J. E. Fischer, and B. S. Graham. 2001. Construction and characterization of recombinant vaccinia viruses co-expressing a respiratory syncytial virus protein and a cytokine. J. Gen. Virol. 82:2107-2116.
23. Johnson, T. R., and B. S. Graham. 1999. Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5), IL-13, and eosinophilia by an IL-4-independent mechanism. J. Virol. 73:8485-8495.
24. Johnson, T. R., J. E. Johnson, S. R. Roberts, G. W. Wertz, R. A. Parker, and B. S. Graham. 1998. Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge. J. Virol. 72:2871-2880.
25. Johnson, T. R., R. A. Parker, J. E. Johnson, and B. S. Graham. 2003. IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge. J. Immunol. 170:2037-2045.
26. Kapikian, A. Z., R. H. Mitchell, R. M. Chanock, R. A. Shvedoff, and C. E. Stewart. 1969. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 89:405-421.
27. Katz, M. E., R. M. Maizels, L. Wicker, A. Miller, and E. E. Sercarz. 1982. Immunological focusing by the mouse major histocompatibility complex: mouse strains confronted with distantly related lysozymes confine their attention to very few epitopes. Eur. J. Immunol. 12:535-540.
28. Kim, H. W., J. G. Canchola, C. D. Brandt, G. Pyles, R. M. Chanock, K. Jensen, and R. H. Parrott. 1969. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89:422-434.
29. Kim, H. W., S. L. Leikin, J. Aerobic, C. D. Brandt, R. M. Chanock, and R. H. Parrott. 1976. Cell-mediated immunity to respiratory syncytial virus induced by inactivated vaccine or by infection. Pediatr. Res. 10:75-78.
30. Lambert, D. M. 1988. Role of oligosaccharides in the structure and function of respiratory syncytial virus glycoproteins. Virology 16:458-466.
31. Levine, S., R. Franco-Klaiber, and P. R. Paradiso. 1987. Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus. J. Gen. Virol. 68:2521-2524.
32. Mendes-da-Cruz, D. A., J. de Meis, V. Cotta-de-Almeida, and W. Savino. 2003. Experimental Trypanosoma cruzi infection alters the shaping of the central and peripheral T-cell repertoire. Microb. Infect. 5:825-832.
33. Morgan, L. A., E. G. Routledge, M. M. Willcocks, A. C. R. Samson, R. Scott, and G. L. Toms. 1987. Strain variation of respiratory syncytial virus. J. Gen. Virol. 68:2781-2788.
34. Murphy, B. R., D. W. Alling, M. H. Snyder, E. E. Walsh, G. A. Prince, R. M. Chanock, V. G. Hemming, W. J. Rodriguez, H. W. Kim, B. S. Graham, and P. F. Wright. 1986. Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection. J. Clin. Microbiol. 24:894-898.
35. Neuzil, K. M., J. E. Johnson, Y.-W. Tang, J.-P. Prieels, M. Slaoui, N. Gar, and B. S. Graham. 1997. Adjuvants influence the quantitative and qualitative immune response in BALB/c mice immunized with respiratory syncytial virus FG subunit vaccine. Vaccine 15:525-532.
36. Nitta, T., H. Iwata, Y. Mori, H. Takagi, K. Kanetake, Y. Iida, K. Sakamoto, T. Yamada, M. Saio, and H. Hirose. 2003. Specific CTL activity of CD8+ TCR Vbeta14+ T cell in mouse 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Dig. Dis. Sci. 48:2095-2103.
37. Olsson, T., C. Edenius, M. Ferm, P. Samuelson, A. Torrang, E. Wallstrom, M. Khademi, M. Andersson, and L. Arfors. 2002. Depletion of Vbeta5.2/5.3 T cells with a humanized antibody in patients with multiple sclerosis. Eur. J. Neurol. 9:153-164.
38. Openshaw, P. J. M., S. L. Clarke, and F. M. Record. 1992. Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. Int. Immunol. 4:493-500.
39. Peebles, R. S. J., K. Hashimoto, and B. S. Graham. 2003. The complex relationship between respiratory syncytial virus and allergy in lung disease. Viral Immunol. 16:25-34.
40. Piedra, P. A., H. S. Faden, G. Cammussi, D. T. Wong, and P. L. Ogra. 1989. Mechanism of lung injury in cotton rats immunized with formalin-inactivated respiratory syncytial virus. Vaccine 124:34-38.
41. Prince, G. A., A. B. Jenson, V. G. Hemming, B. R. Murphy, E. E. Walsh, R. L. Horswood, and R. M. Chanock. 1986. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactivated virus. J. Virol. 57:721-728.
42. Roberts, S. R., D. L. Lichtenstein, L. A. Ball, and G. W. Wertz. 1994. The membrane-associated and secreted forms of the respiratory syncytial virus attachment glycoprotein G are synthesized from alternative initiation codons. J. Virol. 68:4538-4546.
43. Shay, D. K., R. C. Holman, R. D. Newman, L. L. Liu, J. W. Stout, and L. J. Anderson. 1999. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 282:1440-1446.
44. Sparer, T. E., S. Matthews, T. Hussell, A. J. Rae, B. Garcia-Barreno, J. A. Melero, and P. J. M. Openshaw. 1998. Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia. J. Exp. Med. 187:1921-1926.
45. Srikiatkhachorn, A., and T. J. Braciale. 1997. Virus-specific memory and effector T lymphocytes exhibit different cytokine responses to antigens during experimental murine respiratory syncytial virus infection. J. Virol. 71:678-685.
46. + T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J. Exp. Med. 186:421-432.
47. Srikiatkhachorn, A., W. Chang, and T. J. Braciale. 1999. Induction of Th-1 and Th-2 responses by respiratory syncytial virus attachment glycoprotein is epitope and major histocompatibility complex independent. J. Virol. 73:6590-6597.
48. Tang, Y.-W., and B. S. Graham. 1994. Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with respiratory syncytial virus. J. Clin. Investig. 94:1953-1958.
49. Tang, Y.-W., and B. S. Graham. 1997. T cell source of Type 1 cytokines determines illness patterns in respiratory syncytial virus-infected mice, J. Clin. Investig. 99:2183-2191.
50. Tang, Y.-W., K. M. Neuzil, J. E. Fischer, F. W. Robinson, R. A. Parker, and B. S. Graham. 1997. Determinants and kinetics of cytokine expression patterns in lungs of vaccinated mice challenged with respiratory syncytial virus. Vaccine 15:597-602.
51. Tebbey, P. W., M. Hagen, and G. E. Hancock. 1998. Atypical pulmonary eosinophilia is mediated by a specific amino acid sequence of the attachment (G) protein of respiratory syncytial virus. J. Exp. Med. 188:1967-1972.
52. d-restricted peptides. Cell. Immunol. 207:59-71.
53. Tripp, R. A., D. Moore, L. Jones, W. M. Sullender, J. Winter, and L. J. Anderson. 1999. Respiratory syncytial virus G and/or SH protein alters Th1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice. J. Virol. 73:7099-7107.
54. + T cells. Immunity 15:637-646.
55. + T cell responses. J. Immunol. 165:6487-6495.